Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;46(1):4-13.
doi: 10.1159/000495771. Epub 2019 Feb 5.

CAR-Expressing Natural Killer Cells for Cancer Retargeting

Stephan Kloess  1   2 , Anna Kretschmer  1 , Lilly Stahl  1 , Stephan Fricke  1 , Ulrike Koehl  1   3   2
Affiliations
Review

CAR-Expressing Natural Killer Cells for Cancer Retargeting

Stephan Kloess et al. Transfus Med Hemother. 2019 Feb.

Abstract

Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.

Keywords: CAR-NK cell; Chimeric antigen receptor; Haematological malignancies; NK-92; Natural killer cells; Solid tumour.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
GMP-compliant manufacturing of CAR-T cells.
See this image and copyright information in PMC

References

    1. Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. OncoImmunology. 2015 Nov;5((4)):e1115178. - PMC - PubMed
    1. Mehta RS, Randolph B, Daher M, Rezvani K. NK cell therapy for hematologic malignancies. Int J Hematol. 2018 Mar;107((3)):262–70. - PMC - PubMed
    1. Abate-Daga D, Davila ML. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. 2016 May;3:16014. - PMC - PubMed
    1. Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018 Feb;39((2)):167–76. - PMC - PubMed
    1. Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol. 2015 Nov;6:578. - PMC - PubMed